One of the most groundbreaking advances in Retinitis Pigmentosa treatment is gene therapy. Since Retinitis Pigmentosa is often caused by specific genetic mutations, gene therapy aims to correct or replace the faulty genes responsible for the disease. The FDA-approved treatment, Luxturna, is a notable example. Luxturna targets a specific mutation in the RPE65 gene, which is responsible for a certain type of Retinitis Pigmentosa.